News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Merck KGaA has continued its diversification effort with a $17bn (€13bn) bid for Sigma Aldrich that will see it battle Thermo Fisher and GE Healthcare for a share of the life sciences tools and supplies market.
Boehringer Ingelheim will pay mRNA drug developer CureVac up to €465m ($600m) for an exclusive global license and development collaboration on CureVac’s potential mRNA vaccine in early clinical development for the treatment of lung cancer.
Reliance Life Sciences has been contracted to make the first Indian biosimilar of J&J’s Remicade (infliximab), though Epirus Biopharmaceuticals says it is looking to Fujifilm for its European supply.
GlaxoSmithKline will not restart production at a vaccine plant in Belgium until an independent investigation determines how liquid contaminated with polio virus was released into the local sewage system.